Abstract | OBJECTIVE: CASE SUMMARY: DISCUSSION: Several risk factors may predispose a patient to developing aminoglycoside ototoxicity: the 1555 chromosomal mutation, preexisting disorders of hearing and balance, hypovolemia, bacteremia, liver and renal dysfunction, and the simultaneous administration of other ototoxic medications. The cumulative dose and duration of aminoglycoside therapy are more important than serum concentrations. Administration of an aminoglycoside followed by furosemide may increase the risk of ototoxicity. The aminoglycoside interacts with the cell membranes in the inner ear, increasing their permeability. This theoretically allows the loop diuretic to penetrate into the cells in higher concentrations, causing more severe damage. CONCLUSIONS:
|
Authors | Duane E Bates, Steve J Beaumont, Barry W Baylis |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 36
Issue 3
Pg. 446-51
(Mar 2002)
ISSN: 1060-0280 [Print] United States |
PMID | 11895059
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Diuretics
- Gentamicins
- Furosemide
|
Topics |
- Anti-Bacterial Agents
(adverse effects)
- Community-Acquired Infections
(drug therapy)
- Diuretics
(adverse effects)
- Drug Synergism
- Female
- Furosemide
(adverse effects)
- Gentamicins
(adverse effects)
- Hearing Loss, Sensorineural
(chemically induced)
- Humans
- Middle Aged
- Pneumonia
(drug therapy)
- Risk Factors
- Urinary Tract Infections
(drug therapy)
|